Class summary at a glance.

Every drug in the Anti-epileptic Agent class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 14tracked in Part D
CY24 Part D spend: $714.8Mcombined across class
Total Rx claims: 11.8M2.5M unique beneficiaries
Generic mfrs (active): 104across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Lamotrigine

Brand: LAMICTAL · 6.6M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 1995-01-17

22 generic mfrs 104 plans require PA

Low NADAC$0.029

→

Avg plan cost$2.42

Part D spend $327.2M 83× spread, current vs floor

Class share

46%

of class CY24 spend

View profile →

Oxcarbazepine

Brand: OXTELLAR XR · 1.9M Part D claims (CY24) · 384K beneficiaries · First FDA approval: 2000-01-30

21 generic mfrs 0 plans require PA

Low NADAC$0.106

→

Avg plan cost$2.19

Part D spend $177.9M 21× spread, current vs floor

Class share

25%

of class CY24 spend

View profile →

Primidone

Brand: Mysoline · 2.2M Part D claims (CY24) · 564K beneficiaries · First FDA approval: 1978-12-01

7 generic mfrs 0 plans require PA

Low NADAC$0.096

→

Avg plan cost$0.194

Part D spend $70.7M 2× spread, current vs floor

Class share

10%

of class CY24 spend

View profile →

Zonisamide

Brand: ZONISADE · 640K Part D claims (CY24) · 141K beneficiaries · First FDA approval: 2000-03-27

7 generic mfrs 235 plans require PA

Low NADAC$0.063

→

Avg plan cost$0.186

Part D spend $57.9M 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Vigabatrin

Brand: SABRIL · 2K Part D claims (CY24) · 307 beneficiaries · First FDA approval: 2009-08-21

16 generic mfrs 1078 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $43.0M

Class share

of class CY24 spend

View profile →

Felbamate

Brand: Felbatol · 38K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 1993-07-29

5 generic mfrs 22 plans require PA

Low NADAC$0.368

→

Avg plan cost$2.50

Part D spend $20.0M 7× spread, current vs floor

Class share

of class CY24 spend

View profile →

Phenytoin

Brand: Dilantin Infatabs · 159K Part D claims (CY24) · 26K beneficiaries · First FDA approval: 1975-07-16

11 generic mfrs 3 plans require PA

Low NADAC$0.084

→

Avg plan cost$0.399

Part D spend $7.5M 5× spread, current vs floor

Class share

of class CY24 spend

View profile →

Valproic Acid

Brand: Valproic · 159K Part D claims (CY24) · 35K beneficiaries · First FDA approval: 1986-07-01

6 generic mfrs 0 plans require PA

Low NADAC$0.034

→

Avg plan cost$0.122

Part D spend $7.2M 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Ethosuximide

Brand: Zarontin · 24K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 2000-09-22

8 generic mfrs 0 plans require PA

Low NADAC$0.092

→

Avg plan cost$0.331

Part D spend $2.3M 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Methsuximide

Brand: Celontin · 2K Part D claims (CY24) · 467 beneficiaries · First FDA approval: 1957-02-08

1 generic mfrs 1 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $920842

Class share

of class CY24 spend

View profile →

Lamotirigine

Brand: Lamotrigine · — Part D claims (CY24) · First FDA approval: 2020-05-14

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lamotrigine Chewable Dispersible

Brand: lamotrigine · — Part D claims (CY24) · First FDA approval: 2016-01-29

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lamotrigine Er

— Part D claims (CY24) · First FDA approval: 2023-05-03

Brand-only (no generics)

Low NADAC$0.371

→

Avg plan cost$0.828

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Lamotrigine Extended Release

— Part D claims (CY24) · First FDA approval: 2013-01-18

Brand-only (no generics)

Low NADAC$0.371

→

Avg plan cost$0.828

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.